BioDelivery Sciences International, Inc. (BDSI)
Chart Events
Performance Outlook
| Previous Close | 5.59 |
| Open | 5.60 |
| Bid | 0.00 x 28000 |
| Ask | 0.00 x 36200 |
| Day's Range | 5.59 - 5.60 |
| 52 Week Range | 2.50 - 5.62 |
| Volume | |
| Avg. Volume | 3,352,473 |
| Market Cap | 577.05M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 6.82 |
| EPS (TTM) | N/A |
| Earnings Date | Mar 07, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BDSI
Related Research
- BioDelivery Sciences InternatioMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Bank of Queensland should generate some interest; China telecom sends out signals of recovery; Want to know who dominates online searching? Google it; and Brookfield Renewable, Kohl's, and Daiichi.RatingFair ValueEconomic MoatyesterdayMorningstar
- GlobeNewswire
Genenta Announces Nomination of Mark A. Sirgo as Chair
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair
- GlobeNewswire
Collegium Completes the Acquisition of BDSI
STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of
- Zacks
Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
